IPP Bureau
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
By IPP Bureau - April 25, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Zydus Lifesciences gets 10 observations from USFDA for Jarod injectable facility
By IPP Bureau - April 25, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
New chemical method could cut waste from drug production
By IPP Bureau - April 25, 2024
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Bristol Myers Squibb and Cellares inks US$ 380 million capacity reservation for the manufacture of CAR T Cell Therapies
By IPP Bureau - April 23, 2024
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
By IPP Bureau - April 23, 2024
Open a printable version of this pageEmail the URL of this page to a friend
Voydeya approved in the EU as add-on treatment to ravulizumab
By IPP Bureau - April 23, 2024
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
Zydus’ new drug application of Desidustat tablets accepted by China Medical System Holdings
By IPP Bureau - April 23, 2024
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Kwality Pharmaceuticals receives approval from INVIMA for Ampoule and Vial product lines
By IPP Bureau - April 23, 2024
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Lupin launches Mirabegron Extended-Release Tablets in US
By IPP Bureau - April 22, 2024
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
Biocon receives approval from SAHPRA for Tacrolimus Capsule
By IPP Bureau - April 22, 2024
Tacrolimus is an immunosuppressant used in the treatment of organ transplant patients
Sentynl Therapeutics receives marketing authorization for Nulibry from UK MHRA
By IPP Bureau - April 22, 2024
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Evotech and Variant Bio partner to develop fibrosis treatment
By IPP Bureau - April 22, 2024
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Boehringer Ingelheim introduces NexGard Spectra for dogs in India
By IPP Bureau - April 22, 2024
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
By IPP Bureau - April 22, 2024
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
Zydus launches Mirabegron ER Tablets in the US
By IPP Bureau - April 22, 2024
Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market
